• JZL184 and Endocannabinoid Modulation: Neuroprotection and B

  2026-07-06

  Explore how JZL184, a potent monoacylglycerol lipase inhibitor, is transforming research on endocannabinoid signaling modulation and neuroprotection. This article delivers advanced insights into mechanistic pathways and practical assay decisions, extending far beyond prevailing protocol guides.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Applied Wor

  2026-07-06

  Unlock high-sensitivity detection of mitochondrial health and apoptosis using the JC-1 Mitochondrial Membrane Potential Assay Kit. This guide translates advanced immunomodulatory research into practical, optimized protocols and troubleshooting strategies for robust mitochondrial function analysis.

• Technical Use of Angiotensin I/II (1-5) in RAS Research

  2026-07-05

  Angiotensin I/II (1-5) provides researchers with a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled modeling of renin-angiotensin system pathways in hypertension and renal studies. Its use is appropriate for blood pressure regulation and aldosterone release assays, but not for peptide signaling applications outside cardiovascular or renal physiology. Strict attention to solubility and storage is required to avoid confounding experimental results.

• AL-8810: Precision Prostaglandin F2α Antagonist in Vascular

  2026-07-04

  AL-8810, a selective prostaglandin F2α antagonist from APExBIO, enables decisive dissection of FP receptor pathways in endometrial and vascular models. Its validated use in both cellular and in vivo workflows allows researchers to precisely interrogate PGF2α signaling, leading to new insights in reproductive and vascular physiology.

• Flubendazole: Strategic Autophagy Modulation for Translation

  2026-07-03

  Explore the mechanistic foundations and strategic value of Flubendazole in autophagy modulation research. This thought-leadership article bridges molecular insight and experimental design, offering practical guidance for translational researchers and positioning Flubendazole as a cornerstone for reproducible, next-generation studies in cancer biology, neurodegenerative diseases, and beyond.

• Imidazoline Antagonists Enhance Insulin Secretion via K+ Cha

  2026-07-03

  This study demonstrates that imidazoline antagonists of α2-adrenoceptors stimulate insulin release from pancreatic β-cells primarily by inhibiting ATP-sensitive potassium channels, rather than by direct α2-adrenoceptor antagonism. The findings clarify a key mechanistic pathway for drug-induced insulin secretion and inform future metabolic and pharmacological research.

• Primidone and Antiepileptics: Inhibition of Human Serum PON1

  2026-07-02

  This study systematically evaluated how clinically important antiepileptic drugs, including Primidone (Mysoline), inhibit human serum paraoxonase 1 (hPON1), a key HDL-associated enzyme. The findings clarify comparative inhibitory mechanisms and provide kinetic parameters essential for interpreting AED effects on oxidative stress and cardiovascular risk in epilepsy management.

• HyperScript™ Reverse Transcriptase for Robust cDNA Synthesis

  2026-07-02

  HyperScript™ Reverse Transcriptase, derived from M-MLV Reverse Transcriptase, demonstrates high thermal stability and reduced RNase H activity. It enables efficient cDNA synthesis from complex or low-abundance RNA templates, supporting applications such as qPCR and transcriptome profiling.

• AO/PI Double Staining Kit: Practical Cell Viability Workflow

  2026-07-01

  The AO/PI Double Staining Kit offers researchers a rapid, reproducible method for distinguishing viable, apoptotic, and necrotic cells using dual fluorescent staining. It is especially suited for cell viability, apoptosis, and necrosis assays across diverse cell types, but should be applied with careful attention to dye stability and protocol specifics to avoid misinterpretation. Not recommended where non-fluorescence-based detection is required or where dye storage/cell type compatibility is not established.

• Optimizing Chondrogenic Differentiation with Alcian Blue & N

  2026-07-01

  The Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5, streamlines mucopolysaccharide detection and nuclei visualization, enhancing reproducibility in mesenchymal stem cell assays and small tissue biopsies. Its acetic acid-free protocol and robust dual-staining chemistry set a new benchmark for high-resolution, research-grade histology.

• AC008406.3 Knockdown Sensitizes Breast Cancer to Docetaxel v

  2026-06-30

  This study identifies the long non-coding RNA AC008406.3 as a suppressor of cuproptosis and a contributor to docetaxel resistance in breast cancer. By knocking down AC008406.3, researchers enhanced cuproptosis and improved chemotherapeutic sensitivity, highlighting a novel molecular target for overcoming drug resistance.

• ASB3 E3 Ligase Targets MAVS to Suppress Antiviral Immunity

  2026-06-30

  This study demonstrates that the E3 ubiquitin ligase ASB3 acts as a negative regulator of antiviral innate immunity by promoting the K48-linked polyubiquitination and degradation of MAVS, thereby limiting type I interferon responses. The findings clarify a crucial host mechanism controlling the intensity of antiviral signaling and provide a framework for dissecting protein interactions in innate immune pathways.

• Resibufogenin Inhibits NLRP3 Inflammasome to Reduce Atherosc

  2026-06-29

  This study demonstrates that resibufogenin (RBG) effectively blocks NLRP3 inflammasome assembly, thereby reducing inflammation, lipid accumulation, and fibrosis in atherosclerotic mouse models. The findings highlight a novel mechanistic pathway for cardiovascular disease intervention and suggest new directions for targeted anti-inflammatory therapies.

• Applied Tumor Workflows with JNJ-26481585 (Quisinostat)

  2026-06-29

  JNJ-26481585 (Quisinostat) empowers translational cancer research by targeting TRIM21-mediated resistance and inducing apoptosis in diverse tumor models. This guide details robust protocols, advanced applications, and troubleshooting insights to maximize reliability and reproducibility.

• CBD Modulates Orofacial Pain and Affective Deficits via Endo

  2026-06-28

  This study demonstrates that cannabidiol (CBD) robustly attenuates both sensory and affective components of orofacial inflammatory pain in mice. By mapping peripheral and central mechanisms—particularly CB1/CB2 receptor-mediated signaling and neuroimmune modulation—the research provides mechanistic evidence for CBD’s translational potential in managing complex pain syndromes with emotional comorbidities.

15677 records 1/1046 page Next 12345 下5页 Last page